Nuvation Bio (NYSE:NUVB – Get Free Report) and MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.
Risk and Volatility
Nuvation Bio has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, MoonLake Immunotherapeutics has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500.
Earnings and Valuation
This table compares Nuvation Bio and MoonLake Immunotherapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvation Bio | $7.87 million | 255.71 | -$567.94 million | ($0.64) | -9.17 |
| MoonLake Immunotherapeutics | N/A | N/A | -$118.94 million | ($3.32) | -5.05 |
MoonLake Immunotherapeutics has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Nuvation Bio and MoonLake Immunotherapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvation Bio | 1 | 1 | 9 | 1 | 2.83 |
| MoonLake Immunotherapeutics | 4 | 5 | 7 | 0 | 2.19 |
Nuvation Bio presently has a consensus price target of $10.40, indicating a potential upside of 77.17%. MoonLake Immunotherapeutics has a consensus price target of $25.77, indicating a potential upside of 53.75%. Given Nuvation Bio’s stronger consensus rating and higher possible upside, research analysts clearly believe Nuvation Bio is more favorable than MoonLake Immunotherapeutics.
Profitability
This table compares Nuvation Bio and MoonLake Immunotherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvation Bio | -813.07% | -54.99% | -38.12% |
| MoonLake Immunotherapeutics | N/A | -55.57% | -45.18% |
Institutional & Insider Ownership
61.7% of Nuvation Bio shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 29.9% of Nuvation Bio shares are owned by company insiders. Comparatively, 12.0% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Nuvation Bio beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.
About Nuvation Bio
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
Receive News & Ratings for Nuvation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvation Bio and related companies with MarketBeat.com's FREE daily email newsletter.
